SBI Securities’s Damora Therapeutics DMRA Stock Holding History

SBI Securities’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$319	Buy	15 +1	+7%	+$28	﹤0.01%	3262
2026 Q2	$364	Hold	14	–	–	﹤0.01%	3147
2026 Q1	$363	Hold	14	–	–	﹤0.01%	3008
2025 Q4	$322	Sell	14 -4	-22%	-$70	﹤0.01%	3040
2025 Q3	$67	Hold	18	–	–	﹤0.01%	3630
2025 Q2	$61	Hold	18	–	–	﹤0.01%	3676
2025 Q1	$56	Hold	18	–	–	﹤0.01%	3615
2024 Q4	$84	Buy	+18	New	+$118	﹤0.01%	3507

Other funds holding DMRA

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Parkside Financial Bank & Trust Saint Louis, Missouri $1.51B AUM 17.86% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

SBI Securities's DMRA Position: Q3 2026 in Review

SBI Securities increased its Damora Therapeutics (DMRA) stake by 7.1% in Q3 2026, buying an estimated $28 and bringing the position to 15 shares worth $319. The position accounts for ﹤0.01% of the portfolio, ranked #3262.

SBI Securities first reported a position in DMRA in Q4 2024 and has held it in 8 quarters since. The position peaked at $364 in Q2 2026. 10 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.

SBI Securities held 15 shares of Damora Therapeutics worth $319 as of Q3 2026.
SBI Securities bought 1 Damora Therapeutics share in Q3 2026, an estimated $28.
Damora Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3262 holding.
SBI Securities first reported a position in Damora Therapeutics in Q4 2024 and has held it in 8 quarters since.
SBI Securities's Damora Therapeutics position peaked at $364 in Q2 2026.
10 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.